The Annual Report (Page 17) highlights Phosphagenics' strong IP. Note the date of patent expiries. Key patents relating to TPM patch delivery expire in late 2031. Therefore, if TPM/Oxycodone patch is ready to launch in 2014, as suggested in the latest Bell Potter Report, the lucky licensee would enjoy 17 years of patent protection.
Compare this with acquiring a new drug. As the 20 year patent clock starts ticking from the time of lodgement of patent, the relatively long time that it takes for a new drug to complete all necessary trials and wait for FDA approval means that the "patent shelf life" of new drugs can be as little as 8-12 years.
Which, IMO, makes investment in the TPM patch a hugely attractive proposition for a Big Pharma compared with a (risky) investment in a novel drug.
annual report, page-14
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 42422233 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 39472334 | 31 |
View Market Depth
| Last trade - 12.16pm 19/11/2024 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable